Today's Health News
BNT162b2 Highly Effective Against Delta Variant in Teens
At seven to 21 days after second dose, estimated effectiveness was 90 percent against infection, 93 percent against symptomatic COVID-19
3 Percent of U.S. Cancer Cases Attributable to Physical Inactivity
Population-attributable fraction varied from 3.9 percent for urinary bladder cancer to 16.9 percent for stomach cancer
Proton Pump Inhibitor Use Tied to Less Severe Periodontal Disease
Patients with periodontitis who use proton pump inhibitors have fewer teeth with elevated probing depths for the gap between teeth and gums
Fibrosis Stages F3, F4 in NAFLD Linked to Higher Mortality Risk
Incidence of all-cause mortality increased with increasing fibrosis stage; increase also seen in liver-related complications
Lanifibranor Reduces Disease Activity in Nonalcoholic Steatohepatitis
In phase 2b trial, more patients with active NASH had reduction in disease activity score with lanifibranor versus placebo
Salmonella Outbreak in 37 States Linked to Imported Onions
So far, there have been 129 hospitalizations, but no deaths
ACG Updates Clinical Guidelines for Benign Anorectal Disorders
Anorectal biofeedback therapy recommended in defecation disorders; biofeedback also recommended in proctalgia syndrome
More Than Half of COVID-19 Survivors Have Postacute Sequelae
Most common sequelae include functional mobility impairments, pulmonary abnormalities, and mental health disorders
FDA Approves First Interchangeable Biosimilar for Inflammatory Diseases
Cyltezo is first interchangeable monoclonal antibody for RA, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, chronic plaque psoriasis
U.S. Spending Up for Cancer Drugs Lacking Evidence of Survival Benefit
From 2017 to 2019, Medicare spending on 10 accelerated approval drugs with lack of overall survival benefit increased to $569 million